Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Atrial fibrillation

A promising new anticoagulant for stroke prevention

Nature Reviews Cardiology volume 7, pages 10–11 (2010)Cite this article

Subjects

A Correction to this article was published on 01 June 2010

Stroke is the leading cause of morbidity and mortality in patients with atrial fibrillation. Whereas warfarin reduces the risk of stroke, its interactions with other drugs and food, individual differences in its efficacy and the need for frequent monitoring make its use inconvenient. Dabigatran etexilate might represent a step forward in the care of patients with atrial fibrillation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. ACTIVE Investigators et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N. Engl. J. Med. 360, 2066–2078 (2009).

  2. Ezekowitz, M. D. et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am. Heart J. 157, 805–810 (2009).

    Article  CAS  Google Scholar 

  3. Connolly, S. J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139–1151 (2009).

    Article  CAS  Google Scholar 

  4. Baetz, B. E. & Spinler, S. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 28, 1354–1373 (2008).

    Article  CAS  Google Scholar 

  5. Baker, W. L., Cios, D. A., Sander, S. D. & Coleman, C. I. Meta-analysis to assess the quality of warfarin anticoagulation in atrial fibrillation patients in the United States. J. Manag. Care Pharm. 15, 244–252 (2009).

    PubMed  Google Scholar 

  6. Levine, M. N., Raskob, G., Beyth, R. J., Kearon, C. & Schulman, S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (3 Suppl.), 287S–310S (2004).

    Article  CAS  Google Scholar 

  7. European Medicines Agency product overview for Pradaxa (dabigatran etexilate) [online], (2009).

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice and Pharmacy Administration, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, 600 S 43rd Street, Philadelphia, 19104, PA, USA

    Sarah A. Spinler

Authors
  1. Sarah A. Spinler
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Spinler, S. A promising new anticoagulant for stroke prevention. Nat Rev Cardiol 7, 10–11 (2010). https://doi.org/10.1038/nrcardio.2009.220

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2009.220

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing